Article: Early results for HAART 200 and HAART 300 Aortic Annuloplasty Devices

ADVERTORIAL Early results for HAART 200 and HAART 300 Aortic Annuloplasty Devices are encouraging - The Duke Children’s Pediatric & Congenital Heart Center (Duke University Medical Center, Durham, USA) treats the entire spectrum of patients with complex congenital heart disease. In this article, Cardiovascular News focuses on how the centre manages patients with congenital aortic valve disease—specifically, their use of the HAART 200 and HAART 300 (both BioStable) internal aortic valve annuloplasty rings.

2019-02-15T05:51:30-06:00February 11th, 2019|In the News|

HAART 200 First Commercial Use

BioStable Science & Engineering, Inc. announced today the first commercial use of the HAART 200 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin were the collaborating surgeons for the procedure.

2018-12-07T17:37:01-06:00September 26th, 2017|Press Release|
Go to Top